You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 1, January 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Statistics and Research Methods
 •Neoplasms
 •Dermatologic Disorders, Other
 •Dermatology, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Dealing With Unanticipated Mortality in a Large Randomized Clinical Trial of Topical Tretinoin

Lisa M. Schilling, MD, MSPH; Robert P. Dellavalle, MD, PhD, MSPH

Arch Dermatol. 2009;145(1):76.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

 . . . I would urge you to cultivate a keenly skeptical attitude toward the pharmacopeia as a whole. . . . —Sir William Osler, 19071

Millions of people have used topical tretinoin to treat acne and photoaging.2-4 In this issue, Weinstock et al5 report an unexpected result that led to the premature halt of their randomized, placebo-controlled Department of Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial designed to determine whether topical tretinoin, 0.1%, cream prevents basal and squamous cell skin cancer in US veterans. Limited topical tretinoin use (up to twice daily to the face and ears) was associated with increased death (end-of-intervention hazard ratio, 1.54; P = .01).

While some argue that topical tretinoin might increase pulmonary-related mortality,6 Weinstock et al5 ultimately reject this explanation and chalk their results up as a chance finding based on the following: (1) minimal systemic absorption of . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Topical Tretinoin Therapy and All-Cause Mortality
Martin A. Weinstock, Stephen F. Bingham, Robert A. Lew, Russell Hall, David Eilers, Robert Kirsner, Mark Naylor, James Kalivas, Gary Cole, Kimberly Marcolivio, Joseph Collins, John J. DiGiovanna, Julia E. Vertrees, and for the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group
Arch Dermatol. 2009;145(1):18-24.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tretinoin: An Established Long-term Safety Profile--Reply
Katz
Arch Dermatol 2009;145:1064-1065.
FULL TEXT  

Long-Term Topical Tretinoin and Excess Mortality in Older Patients
Journal Watch Dermatology 2009;2009:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.